NO309842B1 - Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer - Google Patents

Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer Download PDF

Info

Publication number
NO309842B1
NO309842B1 NO960607A NO960607A NO309842B1 NO 309842 B1 NO309842 B1 NO 309842B1 NO 960607 A NO960607 A NO 960607A NO 960607 A NO960607 A NO 960607A NO 309842 B1 NO309842 B1 NO 309842B1
Authority
NO
Norway
Prior art keywords
flupirtine
drug
treatment
active substance
reflex
Prior art date
Application number
NO960607A
Other languages
English (en)
Norwegian (no)
Other versions
NO960607L (no
NO960607D0 (no
Inventor
Michael Schwarz
Gabriela Pergande
Juergen Engel
Bernd Nickel
Heinz Ulrich
Stefan Szelenyi
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO960607L publication Critical patent/NO960607L/no
Publication of NO960607D0 publication Critical patent/NO960607D0/no
Publication of NO309842B1 publication Critical patent/NO309842B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
NO960607A 1993-08-17 1996-02-15 Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer NO309842B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
PCT/EP1994/002649 WO1995005175A1 (en) 1993-08-17 1994-08-10 The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Publications (3)

Publication Number Publication Date
NO960607L NO960607L (no) 1996-02-15
NO960607D0 NO960607D0 (no) 1996-02-15
NO309842B1 true NO309842B1 (no) 2001-04-09

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960607A NO309842B1 (no) 1993-08-17 1996-02-15 Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer

Country Status (27)

Country Link
US (1) US5721258A (cs)
EP (1) EP0716602B1 (cs)
JP (1) JPH09501664A (cs)
KR (1) KR100341952B1 (cs)
CN (1) CN1086291C (cs)
AT (1) ATE210442T1 (cs)
AU (1) AU694447B2 (cs)
BG (1) BG62430B1 (cs)
BR (1) BR9407293A (cs)
CA (1) CA2169718C (cs)
CZ (1) CZ289040B6 (cs)
DE (2) DE4327516A1 (cs)
DK (1) DK0716602T3 (cs)
EE (1) EE03204B1 (cs)
ES (1) ES2168309T3 (cs)
HR (1) HRP940464A2 (cs)
HU (1) HU227765B1 (cs)
IL (1) IL110681A (cs)
NO (1) NO309842B1 (cs)
NZ (1) NZ273292A (cs)
PT (1) PT716602E (cs)
RU (1) RU2166318C2 (cs)
SK (1) SK283330B6 (cs)
UA (1) UA43351C2 (cs)
WO (1) WO1995005175A1 (cs)
YU (1) YU49215B (cs)
ZA (1) ZA946176B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
EP1034783B1 (en) * 1997-10-27 2004-12-15 Sumitomo Pharmaceuticals Company, Limited Amide derivatives for the treatment of retinal neurodegenerative disorders
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
WO2001039760A2 (en) * 1999-12-01 2001-06-07 Duke University Method of treating batten disease
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
EP1701725B1 (en) * 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
US20080287399A1 (en) * 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
WO2015017565A1 (en) * 2013-07-31 2015-02-05 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and flupirtine
WO2019014547A1 (en) * 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
CN120346203B (zh) * 2025-06-23 2026-01-09 西安交通大学 GluK1受体激动剂在制备治疗慢性疼痛的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
ATE25078T1 (de) * 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
EP0517852B1 (en) * 1990-03-02 2002-07-10 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
IN172468B (cs) * 1990-07-14 1993-08-14 Asta Medica Ag
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
HU227765B1 (en) 2012-02-28
UA43351C2 (uk) 2001-12-17
BR9407293A (pt) 1996-10-01
YU51294A (sh) 1998-05-15
HRP940464A2 (en) 1997-06-30
NO960607L (no) 1996-02-15
EP0716602A1 (en) 1996-06-19
IL110681A0 (en) 1994-11-11
AU7652894A (en) 1995-03-14
YU49215B (sh) 2004-11-25
CA2169718A1 (en) 1995-02-23
US5721258A (en) 1998-02-24
BG100356A (bg) 1996-07-31
KR960703591A (ko) 1996-08-31
IL110681A (en) 1999-08-17
NZ273292A (en) 1999-09-29
SK21496A3 (en) 1997-01-08
EP0716602B1 (en) 2001-12-12
NO960607D0 (no) 1996-02-15
SK283330B6 (sk) 2003-06-03
RU2166318C2 (ru) 2001-05-10
ATE210442T1 (de) 2001-12-15
DE4327516A1 (de) 1995-02-23
PT716602E (pt) 2002-05-31
EE03204B1 (et) 1999-08-16
ES2168309T3 (es) 2002-06-16
DE69429435D1 (de) 2002-01-24
CZ46596A3 (en) 1996-05-15
WO1995005175A1 (en) 1995-02-23
KR100341952B1 (ko) 2003-04-11
DE69429435T2 (de) 2002-06-13
CN1129399A (zh) 1996-08-21
AU694447B2 (en) 1998-07-23
CZ289040B6 (cs) 2001-10-17
DK0716602T3 (da) 2002-03-25
BG62430B1 (bg) 1999-11-30
CA2169718C (en) 2002-11-12
ZA946176B (en) 1995-03-20
HUT75650A (en) 1997-05-28
JPH09501664A (ja) 1997-02-18
HU9600355D0 (en) 1996-04-29
CN1086291C (zh) 2002-06-19

Similar Documents

Publication Publication Date Title
NO309842B1 (no) Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer
Desmeules et al. Contribution of monoaminergic modulation to the analgesic effect of tramadol
HUP0303983A2 (hu) Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére
EP2701707B1 (en) Method of treating dyskinesia
JP4867123B2 (ja) 神経因性疼痛治療剤および神経因性疼痛のモデル動物
Schwarz et al. Antiparkinsonian effect of flupirtine in monoamine-depleted rats
St-Pierre et al. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model
US20180221380A1 (en) Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia
JP6356763B2 (ja) 三叉神経因性痛に伴う疼痛の治療用タペンタドール
CN101742993A (zh) 用于关节病的疼痛治疗的阿索马多
US20160151359A1 (en) Method of Treating Dyskinesia
Contreras et al. Lateralization of spike and wave complexes produced by hallucinogenic compounds in the cat
Schwarz et al. Intrathecal injection of antispastic drugs in rats: muscle relaxant action of midazolam, baclofen, 2-aminophosphonoheptanoic acid (AP7) and tizanidine
CA2836407A1 (en) Method of treating postural reflex abnormality caused by parkinson's disease
AU2004237401B2 (en) Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
Oztekin et al. 2.233 The effectiveness of pramipexole and cabergoline as an adjunct to levodopa in Parkinson's disease
TW201103546A (en) New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives

Legal Events

Date Code Title Description
MK1K Patent expired